昊海生物科技跌超4%去年归母净利同比减少四成至约2.51亿元

动脉网03-02

昊海生物科技(06826)股价下跌超过4%，报24.54港元，成交额达636.14万港元。根据公司公布的2025年度业绩快报，营业总收入约为24.73亿元，同比减少8.33%；归属于母公司所有者的净利润约为2.51亿元，同比大幅下降40.3%；扣除非经常性损益后的净利润约为1.6亿元，同比减少57.67%。业绩下滑主要由于子公司深圳市新产业眼科新技术的营业利润未达预期，并且预计未来将面临人工晶状体...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2616332950?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-02 15:31","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2616332950","market":"hk","top_or_hot":-1,"title":"昊海生物科技跌超4%去年归母净利同比减少四成至约2.51亿元","media":"动脉网","content":"<div>\n<p>昊海生物科技(06826)股价下跌超过4%，报24.54港元，成交额达636.14万港元。根据公司公布的2025年度业绩快报，营业总收入约为24.73亿元，同比减少8.33%；归属于母公司所有者的净利润约为2.51亿元，同比大幅下降40.3%；扣除非经常性损益后的净利润约为1.6亿元，同比减少57.67%。业绩下滑主要由于子公司深圳市新产业眼科新技术的营业利润未达预期，并且预计未来将面临人工晶状体...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302155224a7309226&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>昊海生物科技跌超4%去年归母净利同比减少四成至约2.51亿元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n昊海生物科技跌超4%去年归母净利同比减少四成至约2.51亿元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-02 15:31 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302155224a7309226&s=b><strong>动脉网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>昊海生物科技(06826)股价下跌超过4%，报24.54港元，成交额达636.14万港元。根据公司公布的2025年度业绩快报，营业总收入约为24.73亿元，同比减少8.33%；归属于母公司所有者的净利润约为2.51亿元，同比大幅下降40.3%；扣除非经常性损益后的净利润约为1.6亿元，同比减少57.67%。业绩下滑主要由于子公司深圳市新产业眼科新技术的营业利润未达预期，并且预计未来将面临人工晶状体...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302155224a7309226&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302155224a7309226&s=b","article_id":"2616332950","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302155224a7309226&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2616332950","pubTimestamp":1772436660,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"昊海生物科技股价下跌超过4%，报24.54港元，成交额达636.14万港元。根据公司公布的2025年度业绩快报，营业总收入约为24.73亿元，同比减少8.33%；归属于母公司所有者的净利润约为2.51亿元，同比大幅下降40.3%；扣除非经常性损益后的净利润约为1.6亿元，同比减少57.67%。这些因素共同导致了昊海生物科技2025年度业绩表现不佳。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1161":"生物科技","BK1593":"医美概念股","06826":"昊海生物科技"},"translate_title":"Haohai Biotechnology fell more than 4%. Last year, its net profit attributable to its parent company decreased by 40% year-on-year to about 251 million yuan","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06826":1.5},"content_text":"昊海生物科技(06826)股价下跌超过4%，报24.54港元，成交额达636.14万港元。根据公司公布的2025年度业绩快报，营业总收入约为24.73亿元，同比减少8.33%；归属于母公司所有者的净利润约为2.51亿元，同比大幅下降40.3%；扣除非经常性损益后的净利润约为1.6亿元，同比减少57.67%。业绩下滑主要由于子公司深圳市新产业眼科新技术的营业利润未达预期，并且预计未来将面临人工晶状体产品第二轮国家带量采购导致的产品降价压力，因此对深圳新产业商誉计提减值准备约1.4亿元。此外，美国子公司Aaren Scientific Inc. 所持有的品牌无形资产也出现减值迹象，初步测试后计提减值准备约人民币2498万元。这些因素共同导致了昊海生物科技2025年度业绩表现不佳。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2616332950","isCrawlerRequest":true}